Cardozo L D, Stanton S L, Robinson H, Hole D
Br Med J. 1980 Feb 2;280(6210):281-2. doi: 10.1136/bmj.280.6210.281.
Thirty women with detrusor instability (27 cases idiopathic, and three secondary to multiple sclerosis) completed a double-blind, cross-over trial of the prostaglandin synthetase inhibitor flurbiprofen and a placebo, results being evaluated by questionnaire and cystometry. Frequency, urgency, and urge incontinence were all significantly reduced with flurbiprofen (P less than 0.001, P less than 0.025, and P less than 0.025 respectively), as was the detrusor-pressure rise during bladder filling (P less than 0.01). Side effects, however, occurred in 13 patients while taking flurbiprofen compared with five while taking placebo (P less than 0.025). After the trial 19 patients wished to continue with flurbiprofen. Flurbiprofen is a useful treatment for idiopathic detrusor instability and is well tolerated by most patients.
30名患有逼尿肌不稳定症的女性(27例为特发性,3例继发于多发性硬化症)完成了一项关于前列腺素合成酶抑制剂氟比洛芬和安慰剂的双盲交叉试验,结果通过问卷调查和膀胱测压进行评估。使用氟比洛芬后,尿频、尿急和急迫性尿失禁均显著减少(分别为P<0.001、P<0.025和P<0.025),膀胱充盈期间逼尿肌压力升高也减少(P<0.01)。然而,服用氟比洛芬时有13名患者出现副作用,而服用安慰剂时为5名(P<0.025)。试验结束后,19名患者希望继续服用氟比洛芬。氟比洛芬是治疗特发性逼尿肌不稳定症的有效药物,大多数患者耐受性良好。